Compare Bristol-Myers Squibb Co (BMY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.68 (market cap $129.94B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SGOV | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $100.74 |
52-Week Low | $42.60 | $100.28 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.51 with minimal daily movement, reflecting its role as a stable cash alternative. The ETF maintains a bearish technical signal from moving averages while oscillators show neutral momentum. Recent institutional activity includes mixed positioning changes, with Bank of America increasing holdings while Deane Retirement Strategies significantly reduced exposure. The fund offers monthly distributions with a current yield around 3.8%, attracting defensive positioning amid market volatility.
SGOV provides principal protection and liquidity with minimal interest rate risk, making it suitable for conservative investors seeking yield above traditional savings. Key risks include Federal Reserve policy changes impacting short-term rates and inflation dynamics affecting real returns. The ETF's stability and monthly income stream offer defensive characteristics during economic uncertainty, though limited upside potential compared to equity investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
